Remove 2024 Remove Drug Pricing Remove Pharmaceutical Companies
article thumbnail

STAT+: An ‘insane’ calculus: A pharma company raised price for a rare disease drug 150% to cover Medicaid rebates

STAT

Four months ago, a small pharmaceuticals company bought a medicine used to combat a rare growth disorder in children and quickly raised the list price by 150%. But the company, Eton Pharmaceuticals, argues there is no other way to keep its treatment on the market and make a profit.

article thumbnail

STAT+: Pharma execs donated more to Democrats in campaign’s final stretch

STAT

WASHINGTON — Most executives at pharmaceutical companies haven’t directly donated to political candidates over the final stretch of the 2024 campaign. 30, five gave to Democratic candidates, even though Democratic lawmakers passed the most aggressive drug pricing reform in decades in 2022. 

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: As Humira biosimilars take over the market, CVS has created a new ploy: the drug ‘rebate credit’

STAT

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies. Continue to STAT+ to read the full story…

article thumbnail

BCG-OPPI report: Winning in the Indian healthcare market to unlock disruptive growth

Express Pharma

Organisation of Pharmaceutical Producers of India (OPPI) in partnership with BCG has released a new report, titled “Winning in Indian Healthcare”. Global pharmaceutical companies have played a pivotal role in transforming the healthcare sector in India.

article thumbnail

Opinion: STAT+: Genentech executive Fritz Bittenbender: Beware political soundbites

STAT

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential campaign — and what their hopes are for a new presidential administration. You

article thumbnail

India Ratings and Research maintains Neutral Outlook for pharmaceuticals sector in FY26

Express Pharma

The Indian pharmaceuticals market (IPM) is projected to grow by 8 per cent year-on-year in FY26, supported by a 4 per cent-5 per cent increase in drug prices, volume growth, and new product launches. Most large pharmaceutical companies rated by Ind-Ra fall into high investment-grade categories.

article thumbnail

Latest CMS Data Reveal the Truth About U.S. Drug Spending

Drug Channels

And contrary to what you might read, drug spending growth was *not* driven by purportedly “skyrocketing” drug prices. In reality, nearly all drug spending growth occurred due to growth in the number of people treated, prescriptions dispensed, and other nonprice factors. healthcare expenditures. healthcare expenditures.